Product Information
EVEROLIMUS 0.5 MG TABLET is a generic product labeled by Breckenridge Pharmaceutical Inc., priced at $3.5246 per EA under NDC 51991038060. Its NADAC has been published 198 times since Dec 21, 2022.
FDA first approved this application on May 20, 2021. Its Orange Book therapeutic-equivalence code is AB — FDA rates it therapeutically equivalent to (substitutable for) its reference product.
Strength
.5 mg/1
Manufacturer
Breckenridge Pharmaceutical Inc.NDC
51991038060
Classification
Generic
Dosage Form
TABLET
Route
ORAL
Effective Date
9/23/2026
Active Ingredients
EVEROLIMUSApproval Type
Generic (ANDA)
FDA Application
ANDA205432FDA Approved
5/20/2021
TE Code
AB
On Market Since
5/21/2021
Pharmacological Classes
Price Statistics
The NADAC for EVEROLIMUS 0.5 MG TABLET has been published 198 times since Dec 21, 2022, and over the history we have for it it has declined 71.9%. The table below summarizes its recorded NADAC range and movement.
| Current price | $3.5246 per EA |
|---|---|
| All-time high | $12.5530 (Mar 15, 2023) |
| All-time low | $3.5246 (Sep 23, 2026) |
| 52-week high | $4.6246 |
| 52-week low | $3.5246 |
| Median price | $4.9030 |
| Average price | $5.5852 |
| Largest weekly change | -59.6% (Mar 22, 2023) |
| Weeks tracked | 198 |
| Tracking since | Dec 21, 2022 |
Generic Alternatives
The matcher finds 1 manufacturer offering a NADAC-published product with this drug's active ingredient and strength in a comparable dosage form (cheapest from each manufacturer, up to 10 shown below). None of the shown alternatives sit below the current price. These are candidates to verify clinically, not guaranteed substitutes — see our generic drug prices guide.
Related Drugs
Same classification
Continue researching this drug
Use these direct paths to move from a single NDC into the surrounding market, manufacturer, class, and trend context.
Manufacturer
Breckenridge Pharmaceutical Inc. manufacturer profile
See the full portfolio, pricing trend, and other products from this labeler.
Drug market
Everolimus tablets market comparison
Compare this molecule across participating manufacturers and inspect the broader market price spread.
Therapeutic class
Kinase Inhibitor class view
See how this drug behaves alongside other products in the same FDA pharmacologic class.
Trend hub
Latest market trends
Zoom back out to the weekly mover view and compare this NDC with the rest of the current NADAC release.
Guide
Understanding NADAC pricing
Use the explainer when you need context on how CMS publishes NADAC and how to interpret the number on this page.
Frequently asked questions
What is the NADAC price of EVEROLIMUS 0.5 MG TABLET?
The current National Average Drug Acquisition Cost (NADAC) for EVEROLIMUS 0.5 MG TABLET, manufactured by Breckenridge Pharmaceutical Inc., is $3.5246 per EA (NDC 51991038060), effective Sep 30, 2026.
How has the price of EVEROLIMUS 0.5 MG TABLET changed over time?
Over the history we have for it, the NADAC for EVEROLIMUS 0.5 MG TABLET has declined 71.9%. It has been tracked across 198 weekly CMS publications since Dec 21, 2022.
What are the highest and lowest recorded NADAC prices for EVEROLIMUS 0.5 MG TABLET?
Since Dec 21, 2022, the NADAC for EVEROLIMUS 0.5 MG TABLET has ranged from a low of $3.5246 (Sep 23, 2026) to a high of $12.5530 (Mar 15, 2023), with a median of $4.9030 per EA.
Are there cheaper alternatives to EVEROLIMUS 0.5 MG TABLET?
1 manufacturer publishes a NADAC-priced product with the same active ingredient and strength as EVEROLIMUS 0.5 MG TABLET in a comparable dosage form, but none are currently priced below it.
Who manufactures EVEROLIMUS 0.5 MG TABLET?
EVEROLIMUS 0.5 MG TABLET (NDC 51991038060) is labeled by Breckenridge Pharmaceutical Inc., and CMS classifies it as a generic product.